Skip to main content

Finck Barbara K's Form 4/A amendment

Amended

Comera Life Sciences Holdings, Inc.CMRA · filed Feb 14, 2023

Accession no.
0001062993-23-003497
Filed
Feb 14, 2023, 5:34 PM ET
Trade date
Jan 4, 2023
Filing delay
41 days
Rule 10b5-1 plan
Not on the form (before 2023)
Original filed
Jan 6, 2023

This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $8.31K. It was filed 41 days after the trade.

This amendment replaces 0001062993-23-000611 (filed Jan 6, 2023).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Finck Barbara KCIK 0001242116Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 4, 2023Common StockPPurchaseAcquired+6,756$1.23F2+$8,309.8823,033Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 4, 2023Common StockPPurchaseAcquired+13,512$0.25+$1,6896,756Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

This Form 4/A is being filed to (i) correct a typographical error in the transaction code disclosed in Column 3 in Table I and Column 4 in Table II in the original Form 4, filed on January 6, 2023, from "A" to "P" and (ii) correct a typographical error in the power-of-attorney of the reporting person.

F2

The reporting person entered into a Securities Purchase Agreement with the Issuer on January 2, 2023, pursuant to which, on January 4, 2023, the reporting person acquired an aggregate of 6,756 units (the "Units") for a purchase price of $1.48 per Unit. Each Unit consists of one share of common stock, par value $0.0001 per share (the "Common Stock"), and one warrant (the "Warrants") to purchase two shares of Common Stock (the "Warrant Shares") at an exercise price of $1.23 per share. Each Warrant is immediately exercisable and expires five years from the date of issuance. The purchase price for each Unit includes $0.125 for each Warrant Share, or $0.25 per Warrant, in accordance with Nasdaq rules.

Referenced by the price of 1 transaction in Table I.

F3

The exercisability of the Warrants is subject to a 9.99% beneficial ownership limitation.

Remarks

Exhibit 24 Power of Attorney filed herewith.

Read the full filing on SEC EDGAR (opens in a new tab)